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Edited by Francesc PosasAbstract Proteasome pathway regulates TGF-b signaling; deg-
radation of activated Smad2/3 and receptors turns TGF-b signal
oﬀ, while degradation of negative modulators such as Ski and
SnoN maintains the signal. We have found that anisomycin is
able to downregulate Ski and SnoN via proteasome as TGF-b
does, but through a mechanism independent of Smad activation.
The mechanism used by anisomycin to downregulate Ski and
SnoN is also independent of MAPK activation and protein syn-
thesis inhibition. TGF-b signal was the only pathway described
causing Ski and SnoN degradation, thus this new eﬀect of aniso-
mycin on endogenous Ski and SnoN proteins suggests alternative
processes to downregulate these negative modulators of TGF-b
signaling.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Transforming growth factor-b (TGF-b) signaling is initiated
by ligand binding to Ser/Thr kinase receptor complexes. This
induces the activation of R-Smads, which form heteromeric
complexes with Smad4 and translocate to the nucleus where
they associate with other transcriptional factors to bind
DNA and regulate the expression of diﬀerent genes. One of
the mechanisms to downregulate TGF-b signaling involves
the interaction of transcriptional co-repressors with Smads
such as TGIF, Ski and SnoN [1–3]. Co-repressors interact di-
rectly with the R-Smad/Smad4 complexes to repress their
transactivation abilities and negatively regulate TGF-b signal-
ing. This results in the inability of TGF-b to inhibit cell prolif-
eration [4,5].
TGF-b/Smad pathway is also controlled by the ubiquitin–
proteasome system. Proteasome is involved in destruction of
TGF-b receptors and Smads whose degradation turns oﬀ
TGF-b signaling [6]. Ski and SnoN co-repressors of TGF-b
signaling are also degraded via the ubiquitin–proteasome path-
way, involving Smurf2 E3 ubiquitin ligase or anaphase–pro-Abbreviations: TGF-b, transforming growth factor-b; IP, immunopre-
cipitation; Aniso, anisomycin; CHX, cycloheximide; Ok ac., okadaic
acid; ChIP, chromatin immunoprecipitation
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doi:10.1016/j.febslet.2005.05.057moting complex (APC) [7,8]. Considering the importance of
the proteasome-mediated degradation of TGF-b signaling
transducers and co-repressors, it is relevant to investigate
whether other signaling pathways can also participate in this
process and modulate TGF-b actions.
TGIF protein stability is regulated positively through
MAPK-dependent phosphorylation [9], which suggests that a
similar mechanism of regulation might also occur for other
co-repressors such as Ski and SnoN. Anisomycin, a protein
synthesis inhibitor, activates MAPK signaling pathways, such
as p38 MAPK and SAPK/JNK as well as ERK1/2 [10–12],
thus, we considered the possibility that anisomycin could be
useful for elucidating if MAP kinases may regulate SnoN
and Ski. Surprisingly, we found that anisomycin causes a rapid
degradation of Ski and SnoN proteins via proteasome but
through a mechanism independent of MAPK activation, pro-
tein synthesis inhibition and Smad activation. This eﬀect is also
cell type speciﬁc, since anisomycin only causes degradation of
these proteins in HeLa and A549 but not in HepG2 cells.2. Materials and methods
2.1. Cell lines and reagents
A549 cells (human lung carcinoma) were maintained in F12-Hams
medium, whereas HeLa (human cervix adenocarcinoma) and HepG2
cells (human hepatoma) were maintained in DMEM, both supple-
mented with 10% fetal bovine serum plus antibiotics. MG132 was ob-
tained from Calbiochem. TGF-b1 was from Pepro Tech. Anisomycin
and cycloheximide (CHX) were from Sigma. MAPK inhibitors:
SB202190, U0126 and SP600125 were from Tocris. Smad2/3, SnoN
and Ski antibodies were from Santa Cruz Biotechnology, and phos-
pho-Smad2 antibody was from Chemicon. Phospho-Erk1/Erk2, phos-
pho-JNK1/JNK2 and phospho-p38 MAPK antibodies were from Cell
Signaling.
2.2. Immunoprecipitations and Western blots
Cells were lysed with TNTE buﬀer (50 mM Tris–HCl buﬀer, pH 7.4,
150 mM NaCl, 5 mM EDTA containing 0.5% Triton X-100 plus a
cocktail of protease and phosphatase inhibitors), then immunoprecipi-
tations and western blots were carried out as described previously [13].
Whole cell lysates (50 lg of protein per lane) were used for western
blots, whereas we used 2 mg of protein for each immunoprecipita-
tion. ERK1/2 were used as control for protein loading and immunob-
lotings were included only in some ﬁgures for clarity. Data showed are
representative from 3 or more independent experiments. Densitometry
was carried out with the Kodak Electrophoresis Documentation and
Analysis System (EDAS 290).
2.3. RT-PCR
Total RNA was isolated using TRIzol (Invitrogen). Total RNA
(2 lg) treated with DNAse I was used for cDNA synthesis using ran-
dom hexamers and SuperScripte RT (Invitrogen). PCRs for Smad7blished by Elsevier B.V. All rights reserved.
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ter mix kit (Qiagen). Oligonucleotide primer sequences employed for
Smad7 were: forward primer 5 0 CTCGGTGCTCAAGAAACTGAAG
3 0 and reverse primer 5 0 GACAGTCTGCAGTTGTGGTTTGAG 3 0.
PCR proﬁles for each primer pair were initially standardized over a
series of cycle numbers to assure that all experimental reactions were
performed within the linear range.
2.4. Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation was carried out as described previ-
ously [14]. The antibodies used were: 5 ll of anti-Ski, 5 ll of anti-
Smad2/3 and 5 ll of goat IgG as a negative control. The Smad7
SBE (Smad Binding Element) is localized at 210. The primer 5 0
TAGAAACCCGATCTGTTGTTTGCG 3 0 (smad7 promoter se-
quence 274 to 251) and the primer 5 0 CCTCTGCTCGGCTGGTT
CCACTGC 3 0 (smad7 promoter sequence 142 to 165) were used to
amplify the fragment of the smad7 promoter. The downstream pair of
primers 5 0 CTCGGTGCTCAAGAAACTGAAG 3 0 (smad7 +586 to
+607) and 5 0GACAGTCTGCAGTTGGTTTGAG 3 0 (smad7 +950
to +971) served as negative controls.3. Results and discussion
3.1. Anisomycin downregulates Ski and SnoN
TGIF, Ski and SnoN co-repressors regulate negatively TGF-
b signaling at the transcriptional level, through binding the
active Smad complexes and recruiting HDAC complexes [3].
Recently, it was reported that activation of the ERK signaling
pathway causes phosphorylation and stabilization of TGIF
protein [9]. In our study, we wanted to evaluate if MAPKs also
played a role in the regulation of Ski and SnoN co-repressors
using anisomycin, a strong activator of MAPK pathways.
Unexpectedly, anisomycin caused SnoN degradation in A549
cells and degradation of Ski and SnoN in HeLa but not in
HepG2 cells. In contrast, TGF-b caused degradation of Ski
and SnoN in all cell lines, except Ski in A549 cells where Ski
seems not to be expressed. Anisomycin eﬀect was dose-depen-Fig. 1. Anisomycin downregulates Ski and SnoN in HeLa and A549 cells bu
alone or with diﬀerent concentrations of anisomycin or with 0.3 nM TGF-
anisomycin at diﬀerent time points. (C) HepG2 cells were incubated for 1 h
immunoprecipitation (IP) with anti-Ski or anti-SnoN antibodies followed by
the lower panels of (A) and (B). Values are expressed as means ± S.E. of thdent and a 10 lM concentration caused a decrease between
60% and 90% in Ski and SnoN protein levels in HeLa and
A549 cells (Fig. 1A). The time-course analysis showed a rapid
downregulation of Ski and SnoN, which was evident after
15 min of treatment with 10 lM anisomycin and continued
1 h after treatment in HeLa and A549 cells (Fig. 1B). Intrigu-
ingly, anisomycin did not cause Ski and SnoN degradation in
HepG2 cells but TGF-b clearly did it (Fig. 1C). Data suggest
that anisomycin eﬀect on Ski and SnoN was cell type speciﬁc.
3.2. Anisomycin causes Ski and SnoN degradation via
proteasome
Thus far, TGF-b signal is the only pathway described caus-
ing Ski and SnoN degradation via proteasome [15]. Here, we
showed that anisomycin also causes Ski and SnoN degradation
via proteasome as TGF-b does. HeLa cells were preincubated
2 h with or without 50 lM MG132, a speciﬁc proteasomal
inhibitor, and then cells were incubated with or without
1 lM anisomycin or 0.3 nM TGF-b for 30 min. TGF-b and
anisomycin induced a decrease of SnoN and Ski proteins levels
in the absence of proteasome inhibitor, whereas treatment with
MG132 increased SnoN and Ski basal levels as expected. A
combination of anisomycin or TGF-b with MG132 reduced
more than 90% SnoN and Ski degradation in HeLa cells
(Fig. 2A and B). Similar results for SnoN were obtained in
A549 cells (Fig. 2C and D). Data indicated that anisomycin re-
duces Ski and SnoN levels using the proteasome pathway as
previously shown for TGF-b [7].
3.3. Anisomycin downregulates Ski and SnoN via a mechanism
independent of Smad activation
It is known that TGF-b causes a rapid and transient SnoN
degradation, however SnoN is also upregulated by TGF-b
after prolonged incubation (1 h or longer) involving Smad acti-
vation [17]. We observed in A549 cells that a short incubationt not in HepG2 cells. (A) A549 and HeLa cells were incubated for 1 h
b1 for 30 min. (B) A549 and HeLa cells were incubated with 10 lM
with 10 lM anisomycin or 0.3 nM TGF-b1. Proteins were subjected to
immunoblotting. Dose–response and time-course analyses are shown in
ree separate experiments.
Fig. 2. Anisomycin causes Ski and SnoN degradation via proteasome.
(A) HeLa cells were pretreated 2 h without (control) or with 50 lM
MG132 and then were incubated for 30 min with or without 1 lM
anisomycin or 0.3 nM TGF-b1. (B) Analysis of the eﬀect of anisomy-
cin on Ski and SnoN protein levels in HeLa cells. (C) A549 cells were
pretreated 2 h without (control) or with 50 lM MG132 and then were
incubated for 10 min with or without 10 lM anisomycin. (D) Analysis
of the eﬀect of anisomycin on SnoN protein levels in A549 cells.
Proteins were subjected to immunoprecipitation (IP) with anti-SnoN
or anti-Ski antibodies followed by immunoblotting. Values are
expressed as means ± S.E. of three separate experiments.
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ment for more than 1 h caused an upregulation of SnoN pro-
tein levels (Fig. 3A). In order to assess if downregulation of
SnoN by anisomycin implicated an activation of TGF-b/Smad
pathway, A549 cells were treated 2 or 3 h with or without
10 lM anisomycin or 0.3 nM TGF-b or were treated for 2 orFig. 3. Anisomycin causes Ski and SnoN downregulation independent
of Smad activation in A549 cells. (A) Cells were treated in the absence
or presence of 0.3 nM TGF-b1 for diﬀerent time points. (B) Cells were
treated 2 or 3 h in the absence or presence of 10 lM anisomycin or
0.3 nM TGF-b1 or were treated for 2 or 3 h with TGF-b1 plus
anisomycin but anisomycin was added in the last 0.5 h of TGF-b1
treatment. (C) A549 cells were treated with 10 lM anisomycin for 1, 4
or 22 h (left panel) or cells were pretreated with 10 lM anisomycin for
4 h, but in the last lane cells were washed twice with media to remove
anisomycin and then cultured in medium with 0.2% FBS to complete
22 h\ of incubation (right panel). Proteins were subjected to immuno-
precipitation with speciﬁc anti-SnoN and anti-Smad2/3 antibodies
followed by immunoblotting using anti-SnoN or anti-phospho-Smad2
antibodies.3 h with TGF-b plus anisomycin but anisomycin was added
in the last 0.5 h of TGF-b treatment (Fig. 3B). We assessed
the levels of phospho-Smad2 as a parameter of TGF-b/Smad
pathway activation. Data showed that anisomycin did not in-
duce Smad2 phosphorylation but caused SnoN degradation
even when TGF-b was inducing an upregulation of SnoN
and probably when the mechanism used by TGF-b to down-
regulate SnoN was no longer working. Similar results were ob-
tained when cells were ﬁrst pretreated 10 min with 10 lM
anisomycin and then were incubated with 0.3 nM TGF-b for
2 or 3 h (data not shown). Data showed anisomycin did not
interfere with the Smad activation by TGF-b, however the
SnoN levels were not increased by this cytokine once anisomy-
cin induced downregulation of SnoN. It is possible that aniso-
mycin does not aﬀect Smad-dependent transcriptional
activation of sno gene but clearly downregulates SnoN protein
levels. The mechanism used by TGF-b to downregulate Ski
and SnoN involves activation of Smads and the participation
of ubiquitin ligases such as Smurf2, whereas anisomycin seems
to use a diﬀerent process independent of Smad activation.
However, if anisomycin cause that Ski and SnoN interact with
an ubiquitin ligase remains to be determined.
The eﬀects of anisomycin on SnoN degradation during pro-
longed exposure were assessed in Fig. 3C. A549 cells were trea-
ted with 10 lM anisomycin for 1, 4 or 22 h and data showed
the levels of SnoN protein were low all the time (Fig. 3C, left
panel). However, when cells were treated for 4 h with 10 lM
anisomycin but anisomycin was then removed and cells were
incubated until 22 h, we observed SnoN degradation at 4 h
and then a recovery of SnoN protein levels at 22 h (Fig. 3C,
right panel). The data clearly showed that the eﬀect of aniso-
mycin on SnoN degradation was reverted when this stimulus
was removed.
3.4. Anisomycin downregulates Ski and SnoN via a mechanism
independent of MAPK-activation and protein synthesis
inhibition
Anisomycin is an inhibitor of protein synthesis and also
strongly activates MAP kinase pathways, such as ERKs, p38
and JNKs. Thus, we explored the eﬀects of anisomycin, cyclo-
heximide (CHX, another protein synthesis inhibitor), and
some activators of stress pathways such as hyperosmolarity
(0.5 M NaCl) and okadaic acid (a protein phosphatase inhibi-
tor) on Ski and SnoN protein levels. HeLa cells were treated
1 h with or without 10 lM anisomycin, 0.3 nM TGF-b,
20 lM CHX, 0.5 M NaCl or 10 lM okadaic acid (Ok ac.).
In all treatments except with TGF-b we observed MAPK acti-
vation (p38, JNKs and ERKs). Notably, CHX, NaCl and oka-
daic acid were not able to cause Ski and SnoN degradation
(Fig. 4A). Analysis of A549 cells treated with anisomycin also
showed the presence of activated p38, JNK1/2 and ERK1/2 as
well as SnoN degradation. We also observed an upregulation
of SnoN after 2 h treatment with TGF-b (Fig. 4B). In order
to support that anisomycin uses a mechanism independent of
MAPK to cause Ski and SnoN degradation, we also used spe-
ciﬁc inhibitors of p38 (SB202190), JNKs (SP600125) and
ERKs (U0126). HeLa cells were pretreated 30 min with or
without 10 lM of each MAPK inhibitor and then treated
30 min with or without 10 lM anisomycin. SnoN and Ski were
immunoprecipitated and analyzed by immunoblotting. We ob-
served that anisomycin still caused degradation of Ski and
SnoN in the presence of MAPK inhibitors in HeLa cells and
Fig. 4. Anisomycin downregulates Ski and SnoN through a MAPK-independent mechanism. (A) HeLa cells were incubated for 1 h with or without
10 lM anisomycin alone (Aniso), 10 lM anisomycin but previously pretreated with 0.2 lM anisomycin for 3 h (line marked with \), 0.3 nM TGF-b1,
20 lM CHX, 0.5 M NaCl or 1 lM okadaic acid (Ok ac.). (B) A549 cells were incubated for 1 h with or without 10 lM anisomycin alone (Aniso),
10 lM anisomycin but previously pretreated with 0.2 lM anisomycin for 3 h (line marked with \), or 0.3 nM TGF-b1 for 2 h. (C) HeLa cells or (D)
A549 cells were pretreated 30 mim with or without MAPK inhibitors: 10 lM SB202190, 10 lM SP600125 or 10 lM U0126, and then cells were
incubated for 30 min with 10 lM anisomycin. Proteins were subjected to immunoprecipitation (IP) with anti-Ski or anti-SnoN antibodies followed by
immunoblotting. Total protein extracts (50 lg) were separated in SDS–PAGE and phosphorylated ERK1/2 (p-ERK1 and p-ERK2), p38 (p-p38),
JNK (p-JNK1 and p-JNK2) and ATF2 (p-ATF2) proteins were detected by immunoblotting. ERK1/2 served as loading control.
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cells (Fig. 4C and D). MAPK inhibitors were very eﬃcient
and blocked more than 90% of MAPK activation, seen as
ERK1/2 and ATF2 phosphorylation (lower panels in Fig.
4C). ATF2 is a substrate for JNK and p38 kinases. Therefore,
data showed that activation of MAP kinases or inhibition of
protein synthesis do not play any signiﬁcant role in the aniso-
mycin-induced downregulation of Ski and SnoN, since they
cannot mimic anisomycin eﬀect on Ski and SnoN. Further-
more, anisomycin activates MAPKs and inhibit protein syn-
thesis but it does not cause Ski and SnoN degradation in
HepG2 cells.
Recently, it was reported that anisomycin pretreatment
desensitizes its eﬀects on MAPK activation [16]. We carried
out similar experiments in order to evaluate if we could also
desensitize anisomycin eﬀects on Ski and SnoN degradation.
HeLa cells were pretreated for 3 h with 0.2 lM anisomycin
and then treated 1 h with 10 lM anisomycin. We observed that
MAPKs activation was decreased but that the eﬀect on SnoN
degradation remained (Fig. 4A and B, lane indicated with \).
Data correlated with the results previously reported showingthat anisomycin desensitizes its own eﬀects on MAPK activa-
tion [16], however regarding the case of SnoN degradation, we
could not observe a desensitization of anisomycin eﬀect, which
suggests that anisomycin uses diﬀerent mechanisms in each
case.
3.5. Downregulation of Ski and SnoN by anisomycin modulates
Smad7 expression
Ski and SnoN exert their actions on TGF-b signaling
through transcriptional repression, thus we analyzed if
anisomycin was able to modulate TGF-b signaling, as a con-
sequence of Ski and SnoN degradation. Recently, it was re-
ported that endogenous Ski inhibits Smad7 expression
maintaining its promoter in a repressed state in the absence
of TGF-b through binding to the SBE in conjunction with
Smad4 [14]. Thus far, Smad7 is the only gene reported as
a Ski target. We analyzed whether downregulation of Ski
co-repressor by anisomycin may facilitate the recruitment
of Smads to the smad7 promoter and Smad7 induction by
TGF-b. We performed ChIP assays using HeLa cells treated
for 1 h with 0.5 nM TGF-b, 10 lM anisomycin or with
Fig. 5. Anisomycin causes Ski and SnoN downregulation and mod-
ulates Smad7 expression in HeLa cells. (A) Cells were treated for 1 h
with 0.5 nM TGF-b1, 10 lM anisomycin or TGF-b1 plus anisomycin
and ChIP assays were carried out. Anti-Smad2/3 or anti-Ski antibodies
were used for immunoprecipitations and PCRs were done with primers
spanning the SBE element that ampliﬁed a product of 136 bp from
smad7 promoter. (B) Cells were pretreated 20 min with 20 lM CHX
and then incubated 2 h with or without 0.3 nM TGF-b1, 10 lM
anisomycin or TGF-b1 plus anisomycin. Total RNA was isolated and
RT-PCR was performed for Smad7 and GAPDH.
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Smad2/3 and anti-Ski speciﬁc antibodies and then DNA
complexed with immunoprecipitated proteins was ampliﬁed
by PCR with speciﬁc primers for Smad7 promoter. We ob-
served that in the absence of TGF-b there was no binding of
Smad2/3 complexes to the smad7 promoter region that was
ampliﬁed by PCR, but when cells were treated with TGF-
b or TGF-b plus anisomycin the binding of Smad2/3 com-
plexes were present on the promoter (3-fold increase over
control). On the other hand, the presence of Ski associated
to the smad7 promoter was observed in control cells, but
when TGF-b, anisomycin or the combination of both were
applied to cells there was a decrease of Ski binding to the
smad7 promoter (80% decrease compared to control value),
probably due to the degradation of Ski (Fig. 5A). Negative
controls were done with oligonucleotides spanning a region
in smad7 promoter downstream of SBE or using an unre-
lated antibody for the immunoprecipitation and in both
cases no ampliﬁcation of smad7 promoter fragment was ob-
tained (data not shown).
In order to assess if an increment in Smad7 mRNA expres-
sion could occur after anisomycin treatment and as a conse-
quence of Ski degradation, we performed RT-PCR analysis.
HeLa cells were pretreated with CHX for 20 min and then
incubated 2 h in the absence or presence of 0.3 nM TGF-b,
10 lM anisomycin or TGF-b plus anisomycin. Total RNA
was isolated and RT-PCR analysis was performed for Smad7.
We observed that TGF-b induced Smad7 mRNA expression
(19-fold over control); anisomycin also induced an increase
of Smad7 mRNA expression (7-fold over control) as well as
TGF-b plus anisomycin (18-fold over control) (Fig. 5B). These
experiments were carried out in the presence of CHX, which
did not cause Smad7 induction (see control). Data suggest that
anisomycin induced an increase of Smad7 mRNA expression
probably by Ski degradation and derepressing smad7 gene as
TGF-b does. This also suggests that one important event in
the anisomycin-induced Ski and SnoN downregulation could
be to facilitate TGF-b signaling.4. Concluding remarks
Our study reports a novel action of anisomycin since causes
downregulation of TGF-b signaling co-repressors Ski and
SnoN mediated by the proteasome pathway, but through a
mechanism that does not involve MAPK activation, protein
synthesis inhibition or Smad activation. This eﬀect of anisomy-
cin on Ski and SnoN proteins suggest that exist alternative
processes to downregulate these negative modulators of
TGF-b signaling independent of Smad activation.
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